Javascript must be enabled to continue!
Cysteine-rich angiogenic inducer 61 (CCN1) independently predicts all-cause mortality in patients with dilated cardiomyopathy
View through CrossRef
Abstract
Introduction
Cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) is a member of the CCN family of matricellular proteins exerting key functions in inflammation and fibrotic turnover. Recently it has been shown that CCN1 improves risk stratification for all-cause mortality in ACS patients.
Purpose
Since both inflammation and fibrosis are key processes involved in the pathogenesis of dilated cardiomyopathy (DCM), we aimed to investigate the prognostic value of CCN1 serum levels for survival in a large cohort of DCM patients.
Methods
The cohort compromised patients with a primary diagnosis of DCM, defined as a reduced left ventricular ejection fraction (LVEF <45%) and an increased left ventricular enddiastolic diameter according to the HENRY score (LVEDD according to HENRY >117%) at the time of diagnosis. Exclusion criteria were primary valvular diseases (≥ second degree), acute myocarditis, active infectious diseases, pulmonary diseases, cancer, chronic alcoholism and heart failure of other origins. CCN1 levels were determined in human serum using an enzyme-linked immunosorbent assay (R&D Systems, USA). Multivariable cox regression models for the association between CCN1 and all-cause mortality were adjusted for age, sex, disease duration, LVEF, estimated glomerular filtration rate (eGFR) measured based on the CKD-EPI formula, high-sensitivity C-reactive protein (hs-CRP) and aminoterminal-proB-type natriuretic peptide (NT-proBNP) levels.
Results
306 DCM patients had available biomarker and clinico-demographic data in this single-center cohort (79.3% males) with a mean age of 55.2 years [interquartile range [IQR] 47.9, 64.8]). On average, disease duration was 0.3 years (IQR 0.9, 1.9), LVEF 31% (IQR 25, 37), LVEDD 67.7 mm (IQR 63, 72), and eGFR 91.5 ml/min (IQR 74.1, 102.4). During a median follow-up of 12.5 years (IQR 10.5, 14.1), a total of 114 (37.3%) patients died. Multivariable-adjusted cox regression models revealed an increasing all-cause mortality risk across CCN1 tertiles (p for trend = 0.03), with the highest incidence in the highest tertile (hazard ratio [HR] 1.75; 95%-CI 1.04, 2.94; P=0.034) as compared to the lowest tertile (Figure 1).
Conclusion
CCN1 predicts long-term survival in DCM patients independent of NT-pro-BNP and other risk determinants. Further research needs to evaluate whether this novel biomarker also plays a causal role in the pathogenesis of DCM.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Kerckhoff Foundation Figure 1
Oxford University Press (OUP)
Title: Cysteine-rich angiogenic inducer 61 (CCN1) independently predicts all-cause mortality in patients with dilated cardiomyopathy
Description:
Abstract
Introduction
Cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) is a member of the CCN family of matricellular proteins exerting key functions in inflammation and fibrotic turnover.
Recently it has been shown that CCN1 improves risk stratification for all-cause mortality in ACS patients.
Purpose
Since both inflammation and fibrosis are key processes involved in the pathogenesis of dilated cardiomyopathy (DCM), we aimed to investigate the prognostic value of CCN1 serum levels for survival in a large cohort of DCM patients.
Methods
The cohort compromised patients with a primary diagnosis of DCM, defined as a reduced left ventricular ejection fraction (LVEF <45%) and an increased left ventricular enddiastolic diameter according to the HENRY score (LVEDD according to HENRY >117%) at the time of diagnosis.
Exclusion criteria were primary valvular diseases (≥ second degree), acute myocarditis, active infectious diseases, pulmonary diseases, cancer, chronic alcoholism and heart failure of other origins.
CCN1 levels were determined in human serum using an enzyme-linked immunosorbent assay (R&D Systems, USA).
Multivariable cox regression models for the association between CCN1 and all-cause mortality were adjusted for age, sex, disease duration, LVEF, estimated glomerular filtration rate (eGFR) measured based on the CKD-EPI formula, high-sensitivity C-reactive protein (hs-CRP) and aminoterminal-proB-type natriuretic peptide (NT-proBNP) levels.
Results
306 DCM patients had available biomarker and clinico-demographic data in this single-center cohort (79.
3% males) with a mean age of 55.
2 years [interquartile range [IQR] 47.
9, 64.
8]).
On average, disease duration was 0.
3 years (IQR 0.
9, 1.
9), LVEF 31% (IQR 25, 37), LVEDD 67.
7 mm (IQR 63, 72), and eGFR 91.
5 ml/min (IQR 74.
1, 102.
4).
During a median follow-up of 12.
5 years (IQR 10.
5, 14.
1), a total of 114 (37.
3%) patients died.
Multivariable-adjusted cox regression models revealed an increasing all-cause mortality risk across CCN1 tertiles (p for trend = 0.
03), with the highest incidence in the highest tertile (hazard ratio [HR] 1.
75; 95%-CI 1.
04, 2.
94; P=0.
034) as compared to the lowest tertile (Figure 1).
Conclusion
CCN1 predicts long-term survival in DCM patients independent of NT-pro-BNP and other risk determinants.
Further research needs to evaluate whether this novel biomarker also plays a causal role in the pathogenesis of DCM.
Funding Acknowledgement
Type of funding sources: Public Institution(s).
Main funding source(s): Kerckhoff Foundation Figure 1.
Related Results
JGA‐Derived CCN1 is a Systemically Acting Angiogenic Hormone
JGA‐Derived CCN1 is a Systemically Acting Angiogenic Hormone
The kidneys are major regulatory organs of whole body homeostasis including body fluid and electrolyte balance, blood pressure maintenance, and blood cell production. Renal control...
Macula densa cell angiogenic mechanisms and their therapeutic potential in kidney disease
Macula densa cell angiogenic mechanisms and their therapeutic potential in kidney disease
IntroductionThe neuronally differentiated key sensory and regulatory cells of the macula densa (MD) were recently identified to control resident progenitor cells and endogenous kid...
Keratinocyte-Specific CCN1 Modulation Driven Regulation of Keratinocyte Proliferation and Inflammation in Psoriasis
Keratinocyte-Specific CCN1 Modulation Driven Regulation of Keratinocyte Proliferation and Inflammation in Psoriasis
Abstract
Background: Psoriasis is a chronic autoimmune disease characterized by the hyperproliferation of keratinocytes and inflammatory cell infiltration. CCN1 is a matric...
Data from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
Data from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
<div>Abstract<p>Oncolytic viral therapy has been explored widely as an option for glioma treatment but its effectiveness has remained limited. Cysteine rich 61 (CCN1) i...
Data from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
Data from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
<div>Abstract<p>Oncolytic viral therapy has been explored widely as an option for glioma treatment but its effectiveness has remained limited. Cysteine rich 61 (CCN1) i...
Alcohol exposure promotes MMP9-mediated CCN1 cleavage in esophageal adenocarcinoma
Alcohol exposure promotes MMP9-mediated CCN1 cleavage in esophageal adenocarcinoma
Background: Alcohol consumption has been a risk factor for more than 200
diseases, including esophageal cancer. CCN1, a matricellular protein, is
highly expressed in esophageal squ...
Association between Bisphenol A exposure and dilated cardiomyopathy
Association between Bisphenol A exposure and dilated cardiomyopathy
Abstract
Background
Evidence has identified bisphenol A to have detrimental environmental and health effects. There are f...
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
Background
Takotsubo cardiomyopathy, also known as stress cardiomyopathy and broken heart syndrome, is a transient, non-ischemic cardiomyopathy marked by revers...

